Mattia Boeri
Overview
Explore the profile of Mattia Boeri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boeri M, Sabia F, Ledda R, Balbi M, Suatoni P, Segale M, et al.
Lancet Reg Health Eur
. 2024 Sep;
46:101070.
PMID: 39319217
Background: The proper management of suspicious radiologic findings is crucial to optimize the effectiveness of low-dose computed tomography (LDCT) lung cancer screening trials. In the BioMILD study, we evaluated the...
2.
Boeri M, Signoroni S, Ciniselli C, Gariboldi M, Zanutto S, Rausa E, et al.
Cancer Gene Ther
. 2024 Feb;
31(6):842-850.
PMID: 38332046
Lynch syndrome (LS) is an inherited condition characterized by an increased risk of developing cancer, in particular colorectal cancer (CRC). Microsatellite instability (MSI) is the main feature of (pre)cancerous lesions...
3.
Fortunato O, Huber V, Segale M, Cova A, Vallacchi V, Squarcina P, et al.
Cancer Epidemiol Biomarkers Prev
. 2022 Sep;
31(11):2020-2029.
PMID: 36112827
Background: Low-dose CT (LDCT) screening trials have shown that lung cancer early detection saves lives. However, a better stratification of the screening population is still needed. In this respect, we...
4.
Galli G, Corsetto P, Proto C, Lo Russo G, Ganzinelli M, Rulli E, et al.
Clin Lung Cancer
. 2022 Aug;
23(7):e489-e499.
PMID: 35948460
Introduction: Lipid metabolism impacts immune cell differentiation, activation, and functions, modulating inflammatory mediators, energy homeostasis, and cell membrane composition. Despite preclinical evidence, data in humans lack concerning tumors and immunotherapy...
5.
Gargiuli C, De Cecco L, Mariancini A, Ianno M, Micali A, Mancinelli E, et al.
Front Oncol
. 2022 Aug;
12:911613.
PMID: 35928879
Background: Circulating microRNAs (ct-miRs) are promising cancer biomarkers. This study focuses on platform comparison to assess performance variability, agreement in the assignment of a miR signature classifier (MSC), and concordance...
6.
Pastorino U, Ladisa V, Trussardo S, Sabia F, Rolli L, Valsecchi C, et al.
J Thorac Oncol
. 2022 Jul;
17(11):1276-1286.
PMID: 35908731
Introduction: Cytisine, a partial agonist-binding nicotine acetylcholine receptor, is a promising cessation intervention. We conducted a single-center, randomized, controlled trial (RCT) in Italy to assess the efficacy and tolerability of...
7.
Moro M, Fortunato O, Bertolini G, Mensah M, Borzi C, Centonze G, et al.
Pharmaceuticals (Basel)
. 2022 Mar;
15(3).
PMID: 35337095
Despite improvements in therapies and screening strategies, lung cancer prognosis still remains dismal, especially for metastatic tumors. Cancer stem cells (CSCs) are endowed with properties such as chemoresistance, dissemination, and...
8.
Montomoli E, Apolone G, Manenti A, Boeri M, Suatoni P, Sabia F, et al.
Viruses
. 2022 Jan;
14(1).
PMID: 35062265
The massive emergence of COVID-19 cases in the first phase of pandemic within an extremely short period of time suggest that an undetected earlier circulation of SARS-CoV-2 might have occurred....
9.
Prelaj A, Boeri M, Robuschi A, Ferrara R, Proto C, Lo Russo G, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053597
(1) Background: In advanced non-small cell lung cancer (aNSCLC), programmed death ligand 1 (PD-L1) remains the only biomarker for candidate patients to immunotherapy (IO). This study aimed at using artificial...
10.
Borzi C, Caiola E, Ganzinelli M, Centonze G, Boeri M, Milione M, et al.
J Thorac Oncol
. 2021 Aug;
16(9):e68-e70.
PMID: 34426000
No abstract available.